Dipyridamole binding to proteins in human plasma and tissue culture media

J. Szebeni, J. N. Weinstein

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Dipyridamole (Persantin), a commonly used coronary vasodilator and antithrombotic drug, has been intensively studied for its potential use in combination chemotherapy for cancer, and recently, for acquired immunodeficiency syndrome. However, the strong binding of dipyridamole to proteins in human plasma complicates quantitative extrapolations from in vitro data to the clinic. To aid in such extrapolations, we incubated dipyridamole in human plasma and in tissue culture media containing 10% fetal calf serum (FCS), and determined the equilibrium levels of free drug. In human plasma, after addition of 2 to 10 μmol/L dipyridamole (i.e., in the therapeutically relevant concentration range), the fraction of free drug averaged between 1.9% and 3.5%. In 10% FCS, after addition of 0.08 to 5 μmol/L dipyridamole (i.e., the experimentally relevant concentration range), mean free fractions were in the 75% to 100% range. Relating various total dipyridamole levels in the therapeutically relevant range in human plasma to those in 10% FCS that provided identical fractions of free drug gave ratios in the 24 to 55 range. Thus, a multiplication factor in the above range is suggested for the interconversion of in vitro and in vivo dipyridamole concentrations that provide equivalent levels of free drug.

Original languageEnglish
Pages (from-to)485-492
Number of pages8
JournalJournal of Laboratory and Clinical Medicine
Volume117
Issue number6
Publication statusPublished - 1991

Fingerprint

Plasma (human)
Tissue culture
Dipyridamole
Culture Media
Carrier Proteins
Proteins
Pharmaceutical Preparations
Extrapolation
Serum
Chemotherapy
Combination Drug Therapy
Vasodilator Agents
Acquired Immunodeficiency Syndrome

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Dipyridamole binding to proteins in human plasma and tissue culture media. / Szebeni, J.; Weinstein, J. N.

In: Journal of Laboratory and Clinical Medicine, Vol. 117, No. 6, 1991, p. 485-492.

Research output: Contribution to journalArticle

@article{8ce3f673b15e4c4c9a7a4eba6bfd6b76,
title = "Dipyridamole binding to proteins in human plasma and tissue culture media",
abstract = "Dipyridamole (Persantin), a commonly used coronary vasodilator and antithrombotic drug, has been intensively studied for its potential use in combination chemotherapy for cancer, and recently, for acquired immunodeficiency syndrome. However, the strong binding of dipyridamole to proteins in human plasma complicates quantitative extrapolations from in vitro data to the clinic. To aid in such extrapolations, we incubated dipyridamole in human plasma and in tissue culture media containing 10{\%} fetal calf serum (FCS), and determined the equilibrium levels of free drug. In human plasma, after addition of 2 to 10 μmol/L dipyridamole (i.e., in the therapeutically relevant concentration range), the fraction of free drug averaged between 1.9{\%} and 3.5{\%}. In 10{\%} FCS, after addition of 0.08 to 5 μmol/L dipyridamole (i.e., the experimentally relevant concentration range), mean free fractions were in the 75{\%} to 100{\%} range. Relating various total dipyridamole levels in the therapeutically relevant range in human plasma to those in 10{\%} FCS that provided identical fractions of free drug gave ratios in the 24 to 55 range. Thus, a multiplication factor in the above range is suggested for the interconversion of in vitro and in vivo dipyridamole concentrations that provide equivalent levels of free drug.",
author = "J. Szebeni and Weinstein, {J. N.}",
year = "1991",
language = "English",
volume = "117",
pages = "485--492",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Dipyridamole binding to proteins in human plasma and tissue culture media

AU - Szebeni, J.

AU - Weinstein, J. N.

PY - 1991

Y1 - 1991

N2 - Dipyridamole (Persantin), a commonly used coronary vasodilator and antithrombotic drug, has been intensively studied for its potential use in combination chemotherapy for cancer, and recently, for acquired immunodeficiency syndrome. However, the strong binding of dipyridamole to proteins in human plasma complicates quantitative extrapolations from in vitro data to the clinic. To aid in such extrapolations, we incubated dipyridamole in human plasma and in tissue culture media containing 10% fetal calf serum (FCS), and determined the equilibrium levels of free drug. In human plasma, after addition of 2 to 10 μmol/L dipyridamole (i.e., in the therapeutically relevant concentration range), the fraction of free drug averaged between 1.9% and 3.5%. In 10% FCS, after addition of 0.08 to 5 μmol/L dipyridamole (i.e., the experimentally relevant concentration range), mean free fractions were in the 75% to 100% range. Relating various total dipyridamole levels in the therapeutically relevant range in human plasma to those in 10% FCS that provided identical fractions of free drug gave ratios in the 24 to 55 range. Thus, a multiplication factor in the above range is suggested for the interconversion of in vitro and in vivo dipyridamole concentrations that provide equivalent levels of free drug.

AB - Dipyridamole (Persantin), a commonly used coronary vasodilator and antithrombotic drug, has been intensively studied for its potential use in combination chemotherapy for cancer, and recently, for acquired immunodeficiency syndrome. However, the strong binding of dipyridamole to proteins in human plasma complicates quantitative extrapolations from in vitro data to the clinic. To aid in such extrapolations, we incubated dipyridamole in human plasma and in tissue culture media containing 10% fetal calf serum (FCS), and determined the equilibrium levels of free drug. In human plasma, after addition of 2 to 10 μmol/L dipyridamole (i.e., in the therapeutically relevant concentration range), the fraction of free drug averaged between 1.9% and 3.5%. In 10% FCS, after addition of 0.08 to 5 μmol/L dipyridamole (i.e., the experimentally relevant concentration range), mean free fractions were in the 75% to 100% range. Relating various total dipyridamole levels in the therapeutically relevant range in human plasma to those in 10% FCS that provided identical fractions of free drug gave ratios in the 24 to 55 range. Thus, a multiplication factor in the above range is suggested for the interconversion of in vitro and in vivo dipyridamole concentrations that provide equivalent levels of free drug.

UR - http://www.scopus.com/inward/record.url?scp=0025858627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025858627&partnerID=8YFLogxK

M3 - Article

C2 - 2045716

AN - SCOPUS:0025858627

VL - 117

SP - 485

EP - 492

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 6

ER -